Clensan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clensan

What is Clensan?

Clensan is a medicinal product used primarily as a bowel cleansing agent. It belongs to a class of medications known as osmotic laxatives, which are designed to clear the intestinal tract by promoting frequent bowel movements.

Composition and Mechanism

The formulation typically consists of active ingredients that increase the volume of water in the intestinal lumen. By drawing fluid into the colon, Clensan softens the stool and induces a flushing effect. This process ensures that the walls of the intestines are visible and clear of debris.

Primary Purpose

Clensan is utilized in clinical settings to prepare the gastrointestinal tract for diagnostic or surgical procedures. Its use is essential for ensuring that the internal lining of the bowel can be examined thoroughly and accurately during medical assessments.

Common scenarios where this cleansing process is required include:

  • Diagnostic Imaging: Providing a clear view for radiological examinations of the abdomen.
  • Endoscopic Procedures: Ensuring the colon is sufficiently prepared for direct visual inspection by a healthcare professional.
  • Surgical Preparation: Clearing the digestive tract prior to certain types of surgery to reduce the risk of complications and improve the surgical environment.

Characteristics

As an osmotic agent, Clensan does not rely on stimulating the muscles of the bowel directly. Instead, it works through the physical presence of fluid, which naturally triggers the body's elimination process. The effectiveness of the product is dependent on the thoroughness of the resulting bowel clearance.

What side effects are possible with Clensan?

Possible Side Effects and Safety Information: Clensan

Clensan is regulated under frameworks for biocidal and chemical products, and its documented safety profile reflects hazards associated with an antimicrobial solution concentrate rather than a systemic pharmaceutical medicine. The known risks are primarily related to direct exposure and environmental impact.


Adverse Reaction Profile

System/Exposure Route Documented Effects
Skin (Prolonged/Repeated Contact) Irritation, redness, and potential for dermatitis.
Eyes (Direct Contact) Moderate to serious irritation; symptoms may include stinging, redness, and tearing.
Inhalation (Vapour, Mist, or Spray) Temporary irritation of the respiratory tract, nose, and throat.
Ingestion Gastrointestinal tract irritation, nausea, vomiting, and potential for discomfort.

The severity of these effects is officially stated to be dependent on the concentration of the product and the length of exposure. There are no formal pharmaceutical frequency classifications (e.g., Very Common, Rare) applied to these effects in the regulatory documents.


Safety-Related Restrictions

Official regulatory sources specify key limitations and necessary precautions to manage the potential risks associated with use:

  • Personal Protection: Users are formally advised to wear protective gloves and eye/face protection to avoid direct contact with the solution, especially the concentrate.
  • Environmental Caution: The product contains components classified as harmful to aquatic life with long-lasting effects. Release into the environment, including waterways, must be avoided.
  • Handling: Instructions emphasize avoiding the inhalation of vapours or spray mists. The product is also specified to be kept out of the reach of children.

The regulatory structure emphasizes safe handling practices and personal protective equipment (PPE) as the primary measures to mitigate the documented risks of irritation and environmental harm.

Overdose and Emergency Response

Clensan (chlorfenapyr) is a moderately toxic pesticide, and an overdose can be life-threatening. An overdose occurs when an excessive amount of the substance is ingested, inhaled, or absorbed through the skin, overwhelming the body's systems. There is no specific antidote for Clensan poisoning, and treatment focuses on supportive care and managing symptoms.

Symptoms of Overdose

Symptoms of acute Clensan poisoning can vary in severity and may be delayed. They often involve the central nervous system, respiratory system, and gastrointestinal tract. Characteristic clinical presentations of serious poisoning include high fever and altered mental status. Other signs can include:

System Symptoms
General Fatigue, weakness, dizziness, headache, excessive sweating, or a general decline in health.
Gastrointestinal Nausea, vomiting, acute abdominal pains, diarrhea.
Neurological Mental confusion, muscle twitches, seizures, or unconsciousness.
Respiratory Respiratory irritation, difficulty breathing, or complete respiratory failure.

When to Seek Immediate Help

A suspected Clensan overdose is a medical emergency that requires immediate professional assistance. Do not wait for symptoms to worsen. Call your local emergency services immediately if you or someone else has been exposed to Clensan and is exhibiting any of the following critical signs:

  • Difficulty breathing, slow, shallow, or stopped breathing
  • Loss of consciousness or inability to wake up
  • Seizures or uncontrolled muscle movements
  • Severe abdominal pain, vomiting, or diarrhea
  • Confusion, delirium, or altered mental status

While waiting for emergency personnel, remove contaminated clothing and wash the affected skin with soap and water. If ingested, rinse the mouth thoroughly with water. Do not induce vomiting unless advised by a healthcare professional. Provide all known information about the exposure, including the amount and time the substance was taken.

Therapeutic Uses of Clensan

Quick Facts: Uses of Clensan

Primary Therapeutic Domain Key Action Scope of Support
Environmental Support Assists in sanitizing surfaces Broad-spectrum support against certain organisms
Hygiene Management Contributes to surface cleaning Appropriate for hard surfaces and textiles

Clensan is designed for professional and industrial use as a multi-surface biocidal sanitiser. Its primary purpose is to support hygiene management by providing a cleaning and sanitizing action on various non-porous surfaces and textiles. This product is intended to assist in managing environmental factors by reducing the presence of certain bacteria and viruses.

Clensan supports cleaning and sanitizing protocols for carpets, upholstery, floors, and hard surfaces. This action contributes to a sanitary environment where the presence of certain harmful organisms may be a concern. The formulation is intended to provide effective support against a broad range of organisms, including specific strains of Enterococcus hirae, Staphylococcus aureus, and enveloped viruses such as Influenza H1N1, when utilized according to its intended application.

The usage of Clensan is a component of a comprehensive approach to professional hygiene and surface care.

Eligibility and Restrictions for Use

Who Can and Cannot Use Clensan

Clensan (Betahistine) is officially established for use in adults aged 18 years and over. Regulatory labeling defines specific populations where use is strictly prohibited, restricted, or requires conditional caution. The following table summarizes the primary eligibility status classifications:

Eligibility Status Applicable Population
Contraindicated Patients with Phaeochromocytoma or known hypersensitivity to the active substance or excipients.
Not Recommended Children and adolescents under 18 years due to insufficient data on safety and efficacy.

The medicine should not be used during pregnancy unless deemed clearly necessary, as data on human risk are insufficient. Similarly, use is not recommended during breastfeeding.

For patients with certain comorbidities, caution is advised. This includes individuals with bronchial asthma, a history of peptic ulceration, severe hypotension, or specific allergic skin conditions. Regulatory experience suggests no dose adjustment is necessary for patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe a few interaction patterns for Clensan (Betahistine), primarily involving metabolic and pharmacodynamic mechanisms. No combinations are universally classified as contraindicated solely due to interaction risk.


Documented Interaction Patterns

Substance Class Interaction Type Regulatory Finding
Monoamino-Oxidase (MAO) Inhibitors Pharmacokinetic (Metabolic) May inhibit the metabolism of Betahistine, leading to a potential increase in its plasma concentration. Caution is recommended for co-administration.
Antihistamines (H1 Antagonists) Pharmacodynamic Antagonism Co-administration may result in a mutual attenuation of effect between the two medicinal products, based on their opposing actions on histamine receptors.

Other Administration Considerations

Food: Official product information indicates that the oral tablet may be taken with meals or after meals. This administration timing is noted as a means to mitigate potential mild gastrointestinal complaints, not because of a required interaction barrier.

Alcohol and Herbal Products: Official prescribing documents typically lack specific, formally tested interaction data for alcohol, herbal products, or supplements. As with most medicines, insufficient information exists to confirm the safety of combining complementary remedies with Betahistine.

Mechanism of Action

Central Vestibular Signal Rebalancing

Clensan’s primary mechanism involves the central nervous system, where it acts as an antagonist on the Histamine H3 Receptor ( H3 R), particularly in the brainstem's Vestibular Nuclei. By blocking this presynaptic autoreceptor, the drug increases the release and availability of native histamine, which then stimulates other receptors, modulating the differential neural firing rates between the vestibular pathways. This physiological adjustment accelerates central vestibular compensation, which is a mechanism of neural functional shift in response to asymmetrical input.


Targeted Inner Ear Microcirculatory Modulation

In parallel with its central effects, the drug exerts a localized peripheral action by modulating vascular tone in the inner ear. Clensan's weak partial agonism on the H1 Receptor ( H1 R), combined with the overall increase in local histamine, induces selective vasodilation within the cochlear and labyrinthine microcirculation. This increased blood flow and permeability contribute to the regulation of endolymphatic fluid dynamics and pressure within the inner ear structures, influencing the physiological homeostasis of the balance sensory organs.

Dosage and Administration Information

How Clensan is Used

Clensan, which contains the active substance Betahistine, is administered via the oral route using the tablet formulation. This usage pattern is structured for continuous, long-term administration rather than acute, short-term use.


Official Administration and Dosing

The standard protocol requires the medicine to be taken in divided doses throughout the day, typically either two or three times daily. The total daily dosage for adult patients generally falls within the range of 24 mg to 48 mg, which constitutes the maximum recommended daily amount. Tablets are to be swallowed whole with a glass of water and not chewed.

Usage Instruction Official Protocol Detail
Timing Relative to Meals Taken with or immediately after meals (as advised to mitigate gastric discomfort)
Administration Route Oral (by mouth)
Daily Dose Range 24 mg to 48 mg (total, divided doses)

Population-Specific Use

Specific protocols are established for different patient groups. No specific dose adjustment is required for older adults or patients with known renal or hepatic impairment. However, Clensan is not recommended for the pediatric population (individuals under 18 years) due to insufficient data supporting its efficacy and safety in this age range. Treatment is defined as a continuous course, with the optimal benefits often becoming apparent after a period of several months.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clensan

Evidence for Use in Peripheral Vertigo

Research on Clensan for general peripheral vertigo—a condition characterized by fluctuating or episodic manifestations—includes Randomized Controlled Trials (RCTs) and larger observational studies. These studies primarily monitored patient-reported outcomes describing perceived discomfort and functional imbalance. Findings describe patterns observed in which participants reported lower scores on dizziness severity and functional scales. However, the overall certainty remains low because the evidence quality varies across studies and the variation in study design limits the ability to draw consistent conclusions from the available findings.

Evidence for Use in Ménière's Disease

Dedicated RCTs and systematic reviews have studied Clensan's impact on this condition. Research was monitored to explore whether the drug affected the mean monthly frequency and severity of vertigo attacks. Studies report how symptoms evolved in the observed populations, but findings have been inconsistent. Later, more rigorous studies data show patterns related to no statistically significant difference compared to the control group on the rate of attacks over the course of a year. Uncertainty remains high due to the condition’s pronounced placebo effect reported in clinical trials.

Long-Term Research and Study Duration

The majority of controlled research was evaluated in contexts relevant in trials assessing short-term or episodic symptom patterns (up to several months). Follow-up durations were limited in placebo-controlled trials, meaning there is limited information for long-term outcomes regarding the sustained control of symptoms over many years.

Evaluating Study Quality and Limitations

Experts and regulators assessing the research note that the evidence quality varies across studies and that a significant point of discussion is the reliance on patient-reported outcomes which can be subjective. These factors together lead to the conclusion that the certainty remains low for some of the key therapeutic claims.

What is Still Uncertain About Clensan

Research is ongoing, but several gaps exist. Primarily, definitive evidence for preventing attacks in Ménière's disease did not report a statistically significant difference on this outcome in recent large trials. The data for certain groups remain insufficient, and most research results apply only to the populations studied (generally adults without significant comorbidities).

Frequently Asked Questions (FAQ)

Common questions about Clensan (FAQ)

Q: Why do some people say Clensan made them feel better right away, and others don't?

Official product information indicates that the expected benefits of this medicine may not be immediate. While some users may report feeling better quickly, improvement often begins after one to two weeks, and the greatest perceived benefit is often reported after several months of continuous treatment.

Q: How does Clensan compare generally to other medicines used for the same thing?

Regulatory documents classify the active ingredient in Clensan as a histamine analogue that works specifically on certain histamine receptors to influence the balance system. This mechanism of action is noted to distinguish it from broad central nervous system suppressants (sedatives).

Q: Do I need to change my diet or lifestyle while taking Clensan?

The official product information advises taking the tablet with or immediately after meals to help minimize potential mild stomach discomfort. It is also noted that regulatory guidance indicates that activities requiring alertness, such as driving or operating heavy machinery, are generally advised against if impairment is experienced.

Q: Are there different strengths of Clensan available?

Official packaging information indicates that the medicine is commonly manufactured and available in multiple tablet strengths. These typically include 8 mg, 16 mg, and 24 mg tablets, among the available options.

Q: Is Clensan associated with any specific warnings mentioned in regulatory documents?

Official regulatory documents indicate that special caution is advised for individuals who have certain pre-existing chronic conditions. These include a history of peptic ulcer, bronchial asthma, severe hypotension (very low blood pressure), and specific allergic skin conditions.

Q: Were the clinical trials for Clensan mostly focused on one specific patient group?

Clinical trials and research evidence primarily focused on studying the effects of the medicine in adult populations. Specifically, research results apply to patients diagnosed with conditions such as vestibular vertigo and Ménière's disease.

Q: Does Clensan need to be taken at a specific time of day?

To ensure a consistent amount of the active substance remains in the body, official guidelines advise patients to spread their doses evenly throughout the day. It is also recommended to try and take the dose at approximately the same time each day.

Q: Why is Clensan sometimes confusingly referred to by multiple names online?

Official sources indicate that confusion arises because the product is referred to both by its specific trade name (Clensan) and by its active chemical ingredient (Betahistine). The active ingredient itself is sold globally under various brand names.

Q: Is there a maximum length of time Clensan is recommended for use?

The medicine is generally intended for long-term administration to manage chronic inner ear symptoms. Official guidelines state that continuation of the tablets is intended until a prescribing physician provides instruction to stop.

Q: Is it normal to feel [vague side effect like 'a bit dizzy'] when starting Clensan?

Clinical trials summarized in official documents list headache, nausea, and dyspepsia (a term for indigestion) as common side effects. Mild gastric complaints, such as stomach pain and bloating, may also occur.

Q: Are there any common over-the-counter (OTC) supplements or pain relievers that shouldn't be taken with Clensan?

Regulatory documents explicitly note interactions with Antihistamines (which may reduce the effectiveness of both drugs) and Monoamino-Oxidase (MAO) Inhibitors (which can increase the level of Clensan in the body). Caution is generally advised when combining it with any other medication, including over-the-counter products.

Q: What does the research say about stopping Clensan use?

The advice contained in official documents indicates that stopping treatment on one's own, even if symptoms improve, may result in the return of the original symptoms.

Q: What should I do if I forget to take my Clensan dose?

If a dose is forgotten, the official instruction is to skip the missed dose entirely and take the next scheduled dose at the usual time. Taking two doses together to try and make up for the missed one is generally not recommended.

Q: Is Clensan available in a generic version?

Yes, the active component of Clensan is Betahistine, which is a well-established synthetic compound. As such, the active ingredient is widely available globally under various generic trade names.

Q: Does Clensan cause drowsiness or affect my ability to drive?

Drowsiness is not typically listed as a common or frequent side effect of the medicine. However, regulatory guidance indicates that if impairment is experienced due to dizziness from the underlying condition or the medicine, then activities such as driving or using complex machinery are advised against.

Q: Are headaches a common concern for people starting Clensan?

Yes, official summaries of clinical trials indicate that headache is a common side effect experienced by patients taking this medicine. It is typically listed as a common nervous system disorder.

Q: What are the most serious possible side effects listed for Clensan?

Serious safety reactions reported spontaneously include hypersensitivity reactions. These include severe allergic responses like anaphylaxis and swelling of the face, tongue, or throat known as angioedema.

Q: What is the purpose of the black box warning on Clensan (if applicable)?

Official U.S. Food and Drug Administration (FDA) regulatory documents indicate that the medicine does not carry a Black Box Warning. A Black Box Warning is the strongest safety warning placed on prescription drug labeling.

Q: What are the possible withdrawal symptoms described when stopping Clensan?

Official documents advise that stopping treatment may lead to the return of the original balance symptoms. However, regulatory summaries do not describe or formally classify a specific withdrawal syndrome when treatment is discontinued.

Q: How quickly does Clensan leave the body after the last dose?

According to pharmacokinetic data in official summaries, the medicine is eliminated from the body relatively quickly. The main active component reaches its peak in about one hour, and its excretion is considered virtually complete within 24 hours after the last dose.

Q: What happens if I accidentally take two Clensan doses close together?

Taking too much of the medicine may lead to mild to moderate symptoms such as nausea, somnolence (drowsiness), and abdominal pain. Patients are typically advised to seek medical attention if they suspect an overdose.

How should Clensan be stored and disposed of?

The storage and disposal of Clensan (Betahistine) tablets must strictly follow regulatory guidance to ensure the product's stability and safe environmental handling.

Storage Requirements

Clensan must be stored at ambient temperature, typically defined as below 25 C or 30 C, depending on the formulation. The product should be kept in its original container or package to protect it from moisture and light. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Clensan must not be disposed of in wastewater or household garbage. To comply with environmental protection protocols, the official instruction is to return the medicine to a pharmacist or a designated local collection point for pharmaceutical waste, following all local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clensan found in:

A-Z Index: